VTVT stock forecast
Our latest prediction for vTv Therapeutics, Inc.'s stock price was made on the Jan. 28, 2020 when the stock price was at 2.18$.
In the short term (2weeks), VTVT's stock price should outperform the market by 5.21%. During that period the price should oscillate between -11.12% and +18.74%.
In the medium term (3months), VTVT's stock price should underperform the market by -1.18%. During that period the price should oscillate between -43.18% and +42.32%.Get email alerts
About vTv Therapeutics, Inc.
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.
At the moment the company generates 7M USD in revenues.
On its last earning announcement, the company reported a loss of -0.51$ per share.
The book value per share is -0.75$
Three months stock forecastJan. 28, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|